| Literature DB >> 25786692 |
Arianne C Richard1, Cuiyan Tan2, Eric T Hawley1, Julio Gomez-Rodriguez3, Ritobrata Goswami4, Xiang-Ping Yang5, Anthony C Cruz1, Pallavi Penumetcha1, Erika T Hayes1, Martin Pelletier1, Odile Gabay1, Matthew Walsh6, John R Ferdinand7, Andrea Keane-Myers8, Yongwon Choi6, John J O'Shea5, Aymen Al-Shamkhani9, Mark H Kaplan4, Igal Gery2, Richard M Siegel10, Françoise Meylan1.
Abstract
The TNF family cytokine TL1A (Tnfsf15) costimulates T cells and type 2 innate lymphocytes (ILC2) through its receptor DR3 (Tnfrsf25). DR3-deficient mice have reduced T cell accumulation at the site of inflammation and reduced ILC2-dependent immune responses in a number of models of autoimmune and allergic diseases. In allergic lung disease models, immunopathology and local Th2 and ILC2 accumulation is reduced in DR3-deficient mice despite normal systemic priming of Th2 responses and generation of T cells secreting IL-13 and IL-4, prompting the question of whether TL1A promotes the development of other T cell subsets that secrete cytokines to drive allergic disease. In this study, we find that TL1A potently promotes generation of murine T cells producing IL-9 (Th9) by signaling through DR3 in a cell-intrinsic manner. TL1A enhances Th9 differentiation through an IL-2 and STAT5-dependent mechanism, unlike the TNF-family member OX40, which promotes Th9 through IL-4 and STAT6. Th9 differentiated in the presence of TL1A are more pathogenic, and endogenous TL1A signaling through DR3 on T cells is required for maximal pathology and IL-9 production in allergic lung inflammation. Taken together, these data identify TL1A-DR3 interactions as a novel pathway that promotes Th9 differentiation and pathogenicity. TL1A may be a potential therapeutic target in diseases dependent on IL-9.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25786692 PMCID: PMC5112176 DOI: 10.4049/jimmunol.1401220
Source DB: PubMed Journal: J Immunol ISSN: 0022-1767 Impact factor: 5.422